A business in context

DCOY research notebook

Read the disclosures. Follow the relationships. Keep the dates in view.

Research JSON

Filing timeline

Download filings CSV

SEC submissions · retrieved 2026-10-23 · 8022 issuers; up to 32 recent company reports and 8 ownership-change filings per issuer

  1. 8-K · Current report

    Report date 2026-09-22 · 0001615219-26-000019 · Items 1.01,3.02,7.01,9.01

  2. 8-K · Current report

    Report date 2026-09-14 · 0001615219-26-000016 · Items 5.07

  3. 4 · Ownership change

    Report date 2026-08-31 · 0002148287-26-000002

  4. 4 · Ownership change

    Report date 2026-08-31 · 0002079859-26-000002

  5. 4 · Ownership change

    Report date 2026-08-31 · 0002079512-26-000002

  6. 4 · Ownership change

    Report date 2026-08-31 · 0001769749-26-000003

  7. 4 · Ownership change

    Report date 2026-08-31 · 0001634368-26-000003

  8. 4 · Ownership change

    Report date 2026-08-31 · 0001457289-26-000003

  9. 4 · Ownership change

    Report date 2026-08-31 · 0001329154-26-000003

  10. 4 · Ownership change

    Report date 2026-08-31 · 0001233253-26-000006

  11. 10-Q · Quarterly report

    Report date 2026-06-30 · 0001193125-26-346852

  12. DEF 14A · Proxy statement

    Report date 2026-09-14 · 0001193125-26-332762

  13. 8-K · Current report

    Report date 2026-07-14 · 0001193125-26-304949 · Items 5.07

  14. 8-K · Current report

    Report date 2026-06-26 · 0001193125-26-286737 · Items 1.01,3.02,7.01,9.01

  15. DEF 14A · Proxy statement

    Report date 2026-06-04 · 0001193125-26-256541

  16. 8-K · Current report

    Report date 2026-05-19 · 0001193125-26-230749 · Items 5.08,8.01

  17. 10-Q · Quarterly report

    Report date 2026-03-31 · 0001193125-26-214816

  18. 10-K/A · Annual report

    Report date 2025-12-31 · 0001193125-26-195909

  19. 8-K · Current report

    Report date 2026-03-31 · 0001193125-26-139145 · Items 8.01,9.01

  20. 10-K · Annual report

    Report date 2025-12-31 · 0001193125-26-134897

  21. 8-K · Current report

    Report date 2026-03-05 · 0001193125-26-092748 · Items 3.03,5.03,8.01,9.01

  22. 8-K · Current report

    Report date 2026-02-24 · 0001193125-26-068813 · Items 5.07

  23. DEF 14A · Proxy statement

    Report date 2026-02-24 · 0001193125-26-008944

  24. 8-K · Current report

    Report date 2026-01-08 · 0001615219-26-000013 · Items 5.03,8.01,9.01

  25. 8-K · Current report

    Report date 2025-12-31 · 0001615219-26-000005 · Items 3.01

  26. 8-K · Current report

    Report date 2025-12-31 · 0001615219-26-000003 · Items 5.07

  27. 8-K · Current report

    Report date 2025-12-19 · 0001615219-25-000197 · Items 5.07,7.01,9.01

  28. 8-K · Current report

    Report date 2025-11-18 · 0001615219-25-000168 · Items 5.02

  29. 8-K · Current report

    Report date 2025-11-17 · 0001615219-25-000166 · Items 7.01

  30. 10-Q · Quarterly report

    Report date 2025-09-30 · 0001615219-25-000164

  31. 8-K · Current report

    Report date 2025-11-11 · 0001615219-25-000162 · Items 1.01,2.01,3.02,3.03,5.02,5.03,8.01,9.01

  32. DEF 14A · Proxy statement

    Report date 2024-12-31 · 0001615219-25-000152

  33. 8-K · Current report

    Report date 2025-10-21 · 0001615219-25-000148 · Items 5.02

  34. 8-K · Current report

    Report date 2025-10-10 · 0001615219-25-000145 · Items 8.01,9.01

  35. 8-K · Current report

    Report date 2025-10-06 · 0001615219-25-000142 · Items 8.01

  36. 8-K · Current report

    Report date 2025-09-17 · 0001615219-25-000135 · Items 1.01,3.03,9.01

  37. 8-K · Current report

    Report date 2025-09-04 · 0001615219-25-000125 · Items 8.01,9.01

  38. 8-K · Current report

    Report date 2025-08-27 · 0001615219-25-000119 · Items 8.01

  39. 8-K · Current report

    Report date 2025-08-22 · 0001615219-25-000117 · Items 8.01,9.01

  40. 8-K/A · Current report

    Report date 2025-08-22 · 0001615219-25-000115 · Items 9.01

Reported insider transactions

Download transactions CSV

SEC insider transactions · retrieved 2026-10-23 · 2026 Q3: filings in this completed quarter; not a live transaction feed

Purchases and sales include open-market or private transactions. Grants, exercises and tax withholding are shown separately. Amendments and joint reports can overlap; rows are not a net-buying score. Prices retain the filing's units; consult its footnotes.

Transaction rows by code · counts, not monetary totals
Purchase: 0 transaction rows0PSale: 0 transaction rows0SGrant / award: 10 transaction rows10AExercise / conversion: 0 transaction rows0MTax / exercise payment: 0 transaction rows0FGift: 0 transaction rows0G
P · PurchaseS · SaleA · Grant / awardM · Exercise / conversionF · Tax / exercise paymentG · Gift

10 matching transaction rows.

Transaction / filedReporting ownerTypeSecuritySharesReported price
2026-08-31
2026-09-02
Gauthier Patricia G.A · Grant / award
Acquired
Common Stock2000.00.0
2026-08-31
2026-09-02
Marschel Peter KlausA · Grant / award
Acquired
Common Stock3900.00.0
2026-08-31
2026-09-02
Hibner Barbara LouiseA · Grant / award
Acquired
Common Stock4216.00.0
2026-08-31
2026-09-02
Burleson TessA · Grant / award
Acquired
Common Stock2000.00.0
2026-08-31
2026-09-02
McVicar William K.A · Grant / award
Acquired
Common Stock3000.00.0
2026-08-31
2026-09-02
Lammers PaulA · Grant / award
Acquired
Common Stock2000.00.0
2026-08-31
2026-09-02
Rosenblum Mark JA · Grant / award
Acquired
Common Stock9682.00.0
2026-08-31
2026-09-02
HANISH ARNOLD CA · Grant / award
Acquired
Common Stock3000.00.0
2026-08-31
2026-09-02
PIERCE FREDERICK IIA · Grant / award
Acquired
Common Stock33455.00.0
2026-08-31
2026-09-02
Lieber Jonathan IA · Grant / award
Acquired
Common Stock2000.00.0

Identity & relationships

Wikidata structured data · retrieved 2026-10-23 · 1658 unambiguous CIK-linked entities; coverage is incomplete

These are sourced identity and relationship claims, with incomplete coverage. Headquarters locations do not describe sales, assets or operating exposure.

SEC issuer · 0001615219Decoy Therapeutics Inc.

No parent relationship is available in this import; this is not proof of independence.

No verified LEI join available.

GLEIF legal entity reference data · retrieved 2026-10-23 · 1197 checked identities; 0 unavailable records

Search names and former names
  • Salarius Pharmaceuticals, Inc. · former SEC name · 2019-07-23 to 2026-01-09
  • Flex Pharma, Inc. · former SEC name · 2014-08-06 to 2019-07-22

Revenue in constant purchasing power

USD revenue expressed in 2026-09 consumer-price dollars. Each annual period uses a CPI-U average weighted by the days in its actual reporting interval. This is a purchasing-power comparison, not a company-specific price or volume measure.

Year endedReported USD revenueCPI-adjusted USD revenue
2022-12-31$0$0
2021-12-31$1.84M$2.29M
2020-12-31$5.23M$6.81M
2019-12-31$3.47M$4.57M
2018-12-31$1.95M$2.62M
2017-12-31$1.27M$1.75M

Bureau of Labor Statistics · retrieved 2026-10-23 · 9 selected series; gaps remain missing

Explore the CPI history ↗